Literature DB >> 17576790

Nicotine glucuronidation and the human UDP-glucuronosyltransferase UGT2B10.

Sanna Kaivosaari1, Päivi Toivonen, Leah M Hesse, Mikko Koskinen, Michael H Court, Moshe Finel.   

Abstract

Nicotine biotransformation affects the smoking habits of addicted individuals and therefore their health risk. Using an improved analytical method, we have discovered that the human UDP-glucuronosyltransferase (UGT) 2B10, a liver enzyme previously unknown to conjugate nicotine or exhibit considerable activity toward any compound, plays a major role in nicotine inactivation by direct conjugation with glucuronic acid at the aromatic nitrogen atom. The K(m) value of recombinant UGT2B10 for nicotine (0.29 mM) was similar to that determined for human liver microsomes (0.33 mM), whereas the K(m) value of UGT1A4 for nicotine was almost 10-fold greater (2.4 mM). UGT2B10 was also more active than UGT1A4 in N-glucuronidation of cotinine (oxidative nicotine metabolite), whereas UGT2B7 exhibited only low nicotine glucuronidation activity and was essentially inactive toward cotinine. UGT1A9 did not glucuronidate nicotine or cotinine. Quantitative reverse transcription-polymerase chain reaction showed that UGT2B10 mRNA was exclusively expressed in human liver, whereas UGTs 1A4 and 2B7 were expressed at comparable, although somewhat lower, levels in liver and several other extrahepatic tissues, including kidney and intestine. These findings for UGT2B10 (but not for UGT1A4 and UGT2B7) were mirrored by human tissue activities because nicotine and cotinine glucuronidation rates in intestine microsomes were less than 0.1% that of human liver microsomes. These novel findings solve two seemingly separate questions: which UGT is primarily responsible for nicotine glucuronidation in human liver, and what conjugation reactions are catalyzed by UGT2B10.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17576790     DOI: 10.1124/mol.107.037093

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  32 in total

1.  UGT2B10 genotype influences nicotine glucuronidation, oxidation, and consumption.

Authors:  Jeannette Zinggeler Berg; Linda B von Weymarn; Elizabeth A Thompson; Katherine M Wickham; Natalie A Weisensel; Dorothy K Hatsukami; Sharon E Murphy
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-05-25       Impact factor: 4.254

2.  Low Cotinine Glucuronidation Results in Higher Serum and Saliva Cotinine in African American Compared to White Smokers.

Authors:  Sharon E Murphy; Christopher J Sipe; Kwangsoo Choi; Leah M Raddatz; Joseph S Koopmeiners; Eric C Donny; Dorothy K Hatsukami
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-03-06       Impact factor: 4.254

3.  Olanzapine metabolism and the significance of UGT1A448V and UGT2B1067Y variants.

Authors:  Kathryn Kelly Erickson-Ridout; Junjia Zhu; Philip Lazarus
Journal:  Pharmacogenet Genomics       Date:  2011-09       Impact factor: 2.089

4.  Glucuronidation genotypes and nicotine metabolic phenotypes: importance of functional UGT2B10 and UGT2B17 polymorphisms.

Authors:  Gang Chen; Nino E Giambrone; Douglas F Dluzen; Joshua E Muscat; Arthur Berg; Carla J Gallagher; Philip Lazarus
Journal:  Cancer Res       Date:  2010-09-28       Impact factor: 12.701

5.  Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria.

Authors:  Joel Tarning; Rose McGready; Niklas Lindegardh; Elizabeth A Ashley; Mupawjay Pimanpanarak; Benjamas Kamanikom; Anna Annerberg; Nicholas P J Day; Kasia Stepniewska; Pratap Singhasivanon; Nicholas J White; François Nosten
Journal:  Antimicrob Agents Chemother       Date:  2009-06-29       Impact factor: 5.191

Review 6.  Biomarkers of exposure to new and emerging tobacco delivery products.

Authors:  Suzaynn F Schick; Benjamin C Blount; Peyton Jacob; Najat A Saliba; John T Bernert; Ahmad El Hellani; Peter Jatlow; R Steven Pappas; Lanqing Wang; Jonathan Foulds; Arunava Ghosh; Stephen S Hecht; John C Gomez; Jessica R Martin; Clementina Mesaros; Sanjay Srivastava; Gideon St Helen; Robert Tarran; Pawel K Lorkiewicz; Ian A Blair; Heather L Kimmel; Claire M Doerschuk; Neal L Benowitz; Aruni Bhatnagar
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-05-18       Impact factor: 5.464

7.  Binding free energies for nicotine analogs inhibiting cytochrome P450 2A6 by a combined use of molecular dynamics simulations and QM/MM-PBSA calculations.

Authors:  Haiting Lu; Xiaoqin Huang; Mohamed Diwan M AbdulHameed; Chang-Guo Zhan
Journal:  Bioorg Med Chem       Date:  2014-03-03       Impact factor: 3.641

8.  UGT1A and UGT2B genetic variation alters nicotine and nitrosamine glucuronidation in european and african american smokers.

Authors:  Catherine A Wassenaar; David V Conti; Soma Das; Peixian Chen; Edwin H Cook; Mark J Ratain; Neal L Benowitz; Rachel F Tyndale
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-10-02       Impact factor: 4.254

9.  Nicotine metabolism in African Americans and European Americans: variation in glucuronidation by ethnicity and UGT2B10 haplotype.

Authors:  Jeannette Zinggeler Berg; Jesse Mason; Angela J Boettcher; Dorothy K Hatsukami; Sharon E Murphy
Journal:  J Pharmacol Exp Ther       Date:  2009-09-28       Impact factor: 4.030

10.  Expression levels of uridine 5'-diphospho-glucuronosyltransferase genes in breast tissue from healthy women are associated with mammographic density.

Authors:  Vilde D Haakensen; Margarethe Biong; Ole Christian Lingjærde; Marit Muri Holmen; Jan Ole Frantzen; Ying Chen; Dina Navjord; Linda Romundstad; Torben Lüders; Ida K Bukholm; Hiroko K Solvang; Vessela N Kristensen; Giske Ursin; Anne-Lise Børresen-Dale; Aslaug Helland
Journal:  Breast Cancer Res       Date:  2010-08-27       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.